By the end of 2021, Pfizer and BioNTech expect that Biovac's facility in Cape Town will be incorporated into the vaccine supply chain. Biovac will obtain drug substance from facilities in Europe, with the manufacturing of finished doses to be completed in 2022.

At full operational capacity, the annual production will exceed 100 million finished doses per year, according to the company. All doses will be distributed exclusively within the 55 member states that make up the African Union.

U.S. to donate 500M doses of Pfizer-BioNTech COVID-19 vaccines
The U.S. government is buying 500 million doses of the Pfizer-BioNTech COVID-19 vaccine to distribute to low- and lower middle-income countries and...

Pfizer to study pneumococcal, COVID-19 vaccine combo in older adults
Pfizer has launched a study that is investigating the coadministration of the company's pneumococcal vaccine (20vPnC) and its Pfizer-BioNTech COVID-19...

FDA authorizes Pfizer-BioNTech COVID-19 vaccine for adolescents
The U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to include adolescents...

Pfizer, BioNTech initiate rolling submission of BLA for COVID-19 vaccine
Pfizer and BioNTech announced on Friday that they have started a biologics license application (BLA) with the U.S. Food and Drug Administration for approval...

Pfizer, BioNTech submit expanded CMA to EMA for COVID-19 vaccine
Pfizer and BioNTech announced on Friday they have submitted a variation to the conditional marketing authorization (CMA) for use of their COVID-19 vaccine...